Brand Name : Crizalk
Composition : Crizotinib
Strength availability : 250mg
Manufactured by : Pfizer Ltd
Form : capsules
Pack : 60 capsules
for MORE INFORMATION !!!
Crizalk 250mg belongs to type of tyrosine kinase inhibitor. Kinases are enzymes which are included in many functions, involving cell development and reproduction.
Crizalk 250mg is made specifically for the treatment of a type of lung cancer in which ALK is overactive due to an abnormality in the ALK gene.
Crizalk 250mg is a prescription drug which is used under the supervision of medical practioner
Crizalk 250mg is indicated for the therapy of patients having metastatic non-small cell lung cancer.
Crizalk 250 mg taken orally twice daily for First dose reduction
Crizalk 250 mg taken orally once daily for Second dose reduction
Permanently discontinue if unable to tolerate Crizalk 250 mg taken orally once daily.
Particularly, crizotinibprevents anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteurd'OrigineNantais (RON).
Malformations in the ALK gene result by mutations or translocations may leads expression of oncogenic fusion proteins. somepatients with NSCLC, they have the EML4-ALK gene.
Crizotinib inhibits ALK tyrosine kinase which essentially results in decreasedproliferation of cells which carry the genetic mutation and tumour survivability.
Maximum serum concentration is 4 to 6 hours and bioavailability were 43%.
Volume of distribution is 1772L and plasma protein bounding is 91%
Crizalk metabolised by CYP3A4 and CYP3A5
Crizalk is eliminated via feces 63% and 22% via urine and half -life is 42 hours
Dosage and administration :
Select patients for the treatment with Crizalk based on ALK or ROS1 presences in tumor specimens
The usual dosage of Crizalk is 250mg orally twice in a day
Administer the Crizalk dose with or without food, until disease progression.
Before using Crizalk in some condition, consult with doctor.
Hepatotoxicity causes while treatment with Crizalk
while treatment with Crizalk will causes Interstitial lung disease/pneumonitis.
QT interval prolongation
Severe visual loss
based on mechanism action the drug will cause risk to foetus
Crizalk 250mg Combination with strong or moderate CYP3A4 inhibitors will increase Crizalk plasma concentration
Crizalk200mg concomitant use with strong CYP3A inducers will decrease Crizalk plasma concentration
Crizalk 250mg Interaction with CYP3A substrates will increase plasma concentration of CYP3A substrates
Do not use combination with bradycardia causing drugs
If the patient vomits after taking a dose of Crizalk 250mg or missed to take a dose, then should not to take an extra dose, but to take the next dose at the regular time, skip the missed dose.
Store at 20℃ to 25℃
Crizalk is caused some side effects as follows :
• Infection increased
• Eyesight changes
• Bowel changes
• Feeling sick
• Swelling of hands and feet’s
• Decreased appetite
• Liver changes
• Skin rash